Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

Liu, Li, Mayes, Patrick A., Eastman, Stephen, Shi, Hong, Yadavilli, Sapna, Zhang, Tianqian, Yang, Jingsong, Seestaller-Wehr, Laura, Zhang, Shu-Yun, Hopson, Chris, Tsvetkov, Lyuben, Jing, Junping, Zhang, Shu, Smothers, James, Hoos, Axel · 2015 · Clinical Cancer Research

Published version of a preprint

Abstract

Purpose: To assess the immunologic effects of dabrafenib and trametinib in vitro and to test whether trametinib potentiates or antagonizes the activity of immunomodulatory antibodies in vivo. Experimental Design: Immune effects of dabrafenib and trametinib were evaluated in human CD4+ and CD8+ T cells from healthy volunteers, a panel of human tumor cell lines, and in vivo using a CT26 mouse model. Results: Dabrafenib enhanced pERK expression levels and did not suppress human CD4+ or CD8+ T-cell function. Trametinib reduced pERK levels, and resulted in partial/transient inhibition of T-cell proliferation/expression of a cytokine and immunomodulatory gene subset, which is context dependent. Trametinib effects were partially offset by adding dabrafenib. Dabrafenib and trametinib in BRAF V600E/K, and trametinib in BRAF wild-type tumor cells induced apoptosis markers, upregulated HLA molecule expression, and downregulated certain immunosuppressive factors such as PD-L1, IL1, IL8, NT5E, and VEGFA. PD-L1 expression in tumor cells was upregulated after acquiring resistance to BRAF inhibition in vitro. Combinations of trametinib with immunomodulators targeting PD-1, PD-L1, or CTLA-4 in a CT26 model were more efficacious than any single agent. The combination of trametinib with anti–PD-1 increased tumor-infiltrating CD8+ T cells in CT26 tumors. Concurrent or phased sequential treatment, defined as trametinib lead-in followed by trametinib plus anti–PD-1 antibody, demonstrated superior efficacy compared with anti–PD-1 antibody followed by anti–PD-1 plus trametinib. Conclusion: These findings support the potential for synergy between targeted therapies dabrafenib and trametinib and immunomodulatory antibodies. Clinical exploration of such combination regimens is under way. Clin Cancer Res; 21(7); 1639–51. ©2015 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-2339

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 36 references

Cited by

See all 446

Metadata

Authors
Liu, L., Mayes, P. A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., Yang, J., Seestaller-Wehr, L., Zhang, S.-Y., Hopson, C., Tsvetkov, L., Jing, J., Zhang, S., Smothers, J., & Hoos, A.
Affiliations
  • GlaxoSmithKline (United States) (US)
  • 1Immuno-Oncology and Combination DPU, GlaxoSmithKline, Collegeville, Pennsylvania.
Venue
Clinical Cancer Research
Published
2015-03-31
Volume
21
Issue
7
Pages
1639-1651
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2094481139
Cited by
446
References
36
Citations by year
2026: 17 · 2025: 27 · 2024: 40 · 2023: 42 · 2022: 48 · 2021: 51 · 2020: 48 · 2019: 44 · 2018: 37 · 2017: 43 · 2016: 32 · 2015: 16
FWCI
18.42
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
GlaxoSmithKline
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
dabrafenib, trametinib, BRAF inhibitors, MEK inhibitors, immunomodulatory antibodies, PD-1, PD-L1, CTLA-4, T cell function, ERK1/2 phosphorylation, BRAF V600E mutation, tumor-infiltrating CD8+ T cells, anti-PD-1 combination therapy, sequential therapy, tumor immunosuppression
MeSH terms
Animals, Antineoplastic Agents, Drug Synergism, Female, Humans, Imidazoles, Immunologic Factors, Mice, Inbred BALB C, Oximes, Pyridones, Pyrimidinones, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, MAP Kinase Kinase Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-2339
The paper
Liu, L., Mayes, P. A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., Yang, J., Seestaller-Wehr, L., Zhang, S.-Y., Hopson, C., Tsvetkov, L., Jing, J., Zhang, S., Smothers, J., & Hoos, A. (2015). The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-2339

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.